StocktoriaMedicus Pharma Ltd. MDCX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
-43.84
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Financials | |||
| Operating income | -$34.4M | -$11.2M | -$4.7M |
| Net income | -$47.3M | -$11.2M | -$5.3M |
| Operating cash flow | -$22.8M | -$10.2M | -$4.2M |
| Total assets | $10.1M | $5.6M | $1.9M |
| Total liabilities | $10.0M | $2.5M | $781,609 |
| Shareholders' equity | -$67,554 | $3.1M | $1.1M |
| Ratios | |||
| Return on assets | -469.9% | -197.6% | -280.8% |
| Return on equity | 69990.7% | -355.9% | -478.2% |
| Current ratio | 1.00 | 2.33 | 2.42 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -43.84 (distress)
- Working capital / assets -0.005
- Retained earnings / assets -6.396
- EBIT / assets -3.415
- Equity / liabilities -0.007
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001997296 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.